ProBioGen Signs Therapeutic Protein Process Development Contract with Virdante Pharmaceuticals

(PresseBox) ( Berlin, )
ProBioGen AG ("ProBioGen"), a technology and service provider for the development and production of biopharmaceutical drug substances today announced signing a contract with Virdante Biopharmaceuticals, Inc., a USbased biopharmaceutical development company ("Virdante").

ProBioGen will contribute producer cell line development and process engineering for one of Virdante's proprietary therapeutic proteins. Virdante's protein products are unique in that they incorporate the company's proprietary "Sialic Switch" technology that improves the antiinflammatory properties of an antibody for autoimmune and inflammatory diseases. Virdante selected ProBioGen for its expertise in developing royaltyfree pharmaceutical cell lines and robust, economical processes for GMPmanufacturing.

"We are highly impressed by Virdante's products and strategies and their compelling scientific rationale to improve human proteins. We are excited to contribute our knowledge in harnessing the cellular machinery to maximize productivity for this ambitious project", commented Dr. Volker Sandig, Chief Scientific Officer of ProBioGen.

About Virdante

Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases. Our products incorporate a proprietary "Sialic Switch" technology to improve the antiinflammatory properties of antibodies. Virdante is located in Cambridge, MA. www.virdante.com
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.